Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer

16Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

TRA-8, a monoclonal antibody targeting death receptor, has demonstrated high therapeutic effect for triple negative breast cancer (TNBC) in preclinical models. Tamoxifen, the standard of care for ERα-positive breast cancer, induces apoptosis via ERβ, which commonly presents in TNBC cells. The current study investigates the combination effects of TRA-8 and tamoxifen for TNBC. In vitro assays were implemented with two ERβ-positive TNBC cell lines, SUM159 and 2LMP, and in vivo therapy studies were followed using orthotopic breast tumor mouse models. IC50 of tamoxifen for SUM159 and 2LMP were 29 μM and 38 μM, respectively. Synergy between TRA-8 (0-1000 ng/mL) and tamoxifen (20 μM) was observed for both the cell lines. Tamoxifen (400 mg/kg diet) markedly suppressed the growth of SUM159 tumors for 6 weeks after therapy initiation, but it did not induce antitumor effect for 2LMP tumors. TRA-8 (0.1 mg, weekly, i.p.) successfully arrested the growth of both SUM159 and 2LMP tumors during therapy, but an antagonistic effect was observed when tamoxifen was combined. TRA-8 uptake into tumors was not changed by tamoxifen treatment. Histological analysis confirmed that caspase-3 activation induced by TRA-8 was significantly decreased when tamoxifen was used in combination. In conclusion, our findings suggest that the combined use of TRA-8 and tamoxifen may cause antagonistic effects for TNBC patients. © 2014 Landes Bioscience.

References Powered by Scopus

Cloning of a novel estrogen receptor expressed in rat prostate and ovary

4322Citations
N/AReaders
Get full text

Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A

2037Citations
N/AReaders
Get full text

The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes

1768Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer

391Citations
N/AReaders
Get full text

Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015)

45Citations
N/AReaders
Get full text

Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review

34Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kim, H., Samuel, S. L., Zhai, G., Rana, S., Taylor, M., Umphrey, H. R., … Zinn, K. R. (2014). Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. Cancer Biology and Therapy, 15(8), 1053–1060. https://doi.org/10.4161/cbt.29183

Readers over time

‘15‘16‘17‘18‘20‘21‘23‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

59%

Professor / Associate Prof. 4

24%

Researcher 3

18%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

38%

Agricultural and Biological Sciences 4

31%

Pharmacology, Toxicology and Pharmaceut... 2

15%

Chemistry 2

15%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 7

Save time finding and organizing research with Mendeley

Sign up for free
0